M&A - SWK Holdings Corp

Form Type: 8-K

Filing Date: 2025-04-10

Corporate Action: Acquisition

Type: New

Accession Number: 000162828025017350

Filing Summary: On April 10, 2025, SWK Holdings Corporation completed a significant transaction through a Royalty Sale to SCOF SPV I, LP, involving the sale and assignment of rights to receive royalties and related payments under contracts of its wholly owned subsidiary, SWK Funding LLC. The transaction was previously disclosed in a Form 8-K on March 20, 2025, with the aggregate purchase price approximating $34.0 million in cash and the assumption of certain liabilities by the Purchaser. Additionally, on the same date, the Company announced the declaration of a cash dividend of $4 per share of common stock, payable on May 8, 2025, to stockholders of record as of April 24, 2025.

Document Link: View Document

Form Type: 8-K

Filing Date: 2025-03-20

Corporate Action: Acquisition

Type: New

Accession Number: 000162828025013999

Filing Summary: On March 19, 2025, SWK Holdings Corporation entered into a purchase and sale agreement with SCOF SPV I, L.P. to sell its rights to receive royalties and other amounts under certain contracts owned by SWK Funding LLC. This sale, referred to as the Royalty Sale, is valued at approximately $34 million. A portion of the proceeds from this transaction is expected to be used to declare a cash dividend to stockholders; however, the specific amount and record date will be disclosed upon closing. Additionally, on March 17, 2025, ANI Pharmaceuticals notified SWK Holdings of its intention to exercise a buy-back option on certain royalties, resulting in an estimated gross income of $17.3 million for the company. This document serves to fulfill the regulatory obligations under the Securities Exchange Act and discusses the implications of these transactions along with details of customary representations and warranties included in the Purchase Agreement.

Document Link: View Document